A B S T R AC T
Background. The raw annual mortality rate reported in Chinese patients on maintenance hemodialysis (MHD) was around 10% between 2005 to 2010, and it was around 20% in the US as reported by the United States Renal Data System (USRDS). Our hypothesis was that the large survival difference was caused by differences in race and practice pattern between nations in addition to differences in patient characteristics. , respectively) was much lower than that for whites. The annual mortality for Asian-Americans was slightly lower than that for African-Americans. After adjustment, Beijing MHD still had a survival benefit compared with each of the examined USRDS race. The annual mortality rates were 99.4, 80.6 and 94.3 per 1000 patient-years when adjusted to whites, African-Americans and Asian-Americans, respectively, in cohort 2009. Conclusions. The annual mortality for the Beijing MHD patients was lower than that for their USRDS counterparts, and this difference existed after baseline demographics were adjusted. This survival difference between the Beijing and the USRDS MHD cohorts could be attributed to differences in race or practice pattern. More studies are needed to validate our hypothesis.
I N T RO D U C T I O N
It was in 1999 that the Chinese Society of Nephrology reported the first national end-stage renal disease (ESRD) registration data [1] . Another set of national registration data was reported in 2010 [2] . It can be seen from these two reports that ESRD burden was increasing quickly in the Chinese mainland. Although these data were cross-sectional in nature, they, to some extent, described the ESRD burden during that time period.
The Beijing Hemodialysis Quality Control and Improvement Center (BJHDQCIC) was set up by the Beijing Health Bureau in 2003, and one of the main missions of BJHDQCIC was to do ESRD registration. Before 2007, facility-level data were collected at the end of every year. The number of patients in each of the categories age group, gender, primary cause of ESRD and primary cause of death at the end of the year was collected; the number of new patients who entered hemodialysis and of those who dropped out (including transplant, transfer to peritoneal dialysis and death) were also collected. Summarizing these data, annual incidence, point prevalence, annual mortality, main cause of ESRD and main cause of death were calculated and reported [3, 4] , and the annual mortality rate was reported to be ∼8.8% to 11% in 2003 and 2004. From 2007, BJHDQCIC started collecting patient-level data, i.e. each patient's date of birth, gender, primary cause of ESRD, date of the first dialysis, date of drop-out or death, etc., using a data capturing system, and uploaded them into the Information Center of Beijing Health Bureau. According to the data collected, an annual data report (ADR) was produced. The first ADR was published in 2009 [5] and the second ADR in 2011 [6] . According to ADR 2011, the annual mortality of MHD patients in Beijing was 7.4%, 7.6%, 9.0% and 8. United Renal Data System (USRDS) is a world-renowned ESRD registration system, and ESRD epidemiological patterns are reported by USRDS ADR annually. According to USRDS 2011 [7] , the annual mortality was 156.9, 151.5 and 148. The raw mortality rate of ESRD patients on maintenance hemodialysis (MHD) in Beijing seemed much lower than that reported by the USRDS. But the methods adopted for calculating and reporting annual mortality were different. In the current study, the annual mortality rates for the Beijing and the USRDS MHD patients were calculated using the same method. If the mortality difference is real, the difference might be caused by differences in demographic parameters between these two patient cohorts, such as age, gender and primary cause of ESRD. In the current study, annual mortality rates were compared between the USRDS and the Beijing MHD patients after age, gender and primary cause of ESRD were adjusted. If the annual mortality difference still existed after the adjustment, we hypothesized that the difference was caused by either genetic difference or practice pattern difference.
M E T H O D S
Beijing MHD cohort In 2007, there were 120 hemodialysis facilities in Beijing, among which 107 facilities were under the control of BJHDQCIC. Some of the facilities were closed because of quality issues, and there were 104 running facilities at the end of 2010. Using the RenDER system, male or female MHD patients not <20 years old were selected and 5 cohorts 
Data manipulation
There were 8 kinds of primary causes of ESRD listed by the RenDER system and 10 listed by the Beijing dataset. Diabetes, hypertension and glomerulonephritis were considered primary causes of ESRD; other known, unknown or missing causes were merged as one, named 'other'.
Patient ages were divided into three groups: 20 to 44, 45 to 64 and 65 or older.
USRDS annual mortality
Annual mortalities for each year from 2004 to 2009 were also requested using the RenDER system. Annual mortality was expressed as the number of deaths per 1000 patientyears, and stratified by gender, age group and primary cause of ESRD. We requested the RenDER system to search the 90-Day dataset from 2004 to 2009; we included only white, African-American and Asian-American US residents on MHD not less than 20 years old. These annual mortalities were compared with the mortality in Beijing.
Beijing annual mortality
All the patients in cohort 2007 were at risk of death. Patient-years at risk were calculated, the number of deaths from 1 January 2007 to 31 December 2007 was retrieved and annual mortality rate expressed as the number of deaths per 1000 patient-years. The annual mortality was further stratified by gender, age group and primary cause of ESRD. The mortality of 'other' could not be extracted from the USRDS RenDER system, so only patients with diabetes, hypertension or glomerular nephritis as the primary cause of ESRD were included for annual mortality calculation. When comparing the annual mortality difference between the Beijing cohorts and the USRDS cohorts, the patients diagnosed with 'other' were excluded.
R E S U LT
The Beijing cohort 2007-10 There were 11 675 subjects in the Beijing cohort 2007-10. There were more male patients receiving hemodialysis than females (53.2% versus 46.8%). There were 32.2% subjects 65 years or older. The leading cause of ESRD was glomerulonephritis (20.2%), followed by diabetes mellitus (18.2%) and hypertension (10.1%). Other or unknown causes accounted for 51.4% (Table 1) .
There were a total of 1625 deaths in the cohort. The leading cause of death was cardiovascular disease (34.2%), followed by stroke (14.6%), infection (12.2%) and neoplasm (6.9%). Other or unknown causes of death accounted for 42.6% (Table 1) . 
Comparison of Beijing cohorts with USRDS cohorts

O R I G I N A L A R T I C L E
M o r t a l i t y r a t e s a m o n g p r e v a l e n t American population. The detailed baseline demographics of each of the Chinese and USRDS cohorts are shown in Table 2 . Raw annual mortality rate was calculated for each of the Beijing and USRDS cohorts ( Table 3 Annual mortality was further broken down by gender, age groups and primary cause of ESRD (Table 3 ). It was universal that older patients and diabetic patients had bad survival. As to gender, there was some disparity in the Beijing cohorts: female subjects had relatively lower annual mortality compared with male subjects; on the other hand, in each of the USRDS cohorts, male subjects had lower annual mortality compared with females.
After gender, age group and primary cause of ESRD in each of the Beijing cohorts were adjusted, the annual mortality for each of the Beijing cohorts still remained the lowest among the four races ( 
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D I S C U S S I O N
We found in the current study that the Beijing MHD patients had better survival than their USRDS counterparts and that this survival advantage persisted after age, gender and causes of ESRD were adjusted. The survival difference between the Beijing and the USRDS MHD patients could be attributed to differences in practice pattern or race. It was quite intriguing that the Beijing MHD patients had this survival advantage. There was no good explanation for this phenomenon and further research was needed. However, a few points were worthy of note.
Significant baseline demographic differences between the Beijing cohorts and the URSRDS cohorts might be an explanation for the striking survival difference between Beijing and USRDS. It was fully accepted that older and diabetic F I G U R E 1 : Raw mortality rate ( per 1000 patient-years) for prevalent MHD patients by race and year.
MHD patients had high relative risk of death compared with the young and non-diabetic MHD patients [7] . Compared with the USRDS patients, whether they were white, AfricanAmerican or Asian-American, the Beijing MHD patients were relatively younger, and diabetic ESRD was less prevalent. But the survival advantage still existed in the Beijing MHD patients after age, gender and primary cause of ESRD were adjusted to their counterparts. The survival advantage in the F I G U R E 2 : Adjusted mortality rate ( per 1000 patient-years) for prevalent MHD patients by race and year. Gender, age group and cause of ESRD in Beijing were adjusted to the same year cohort of white, Asian-American and African-American, respectively. Beijing MHD patients could not be fully explained by differences in gender, age or difference in primary cause of ESRD. The difference in clinical practice patterns between USRDS and Beijing should be the most important, if not only, reason to explain the survival difference.
(1) The DOPPS study gives a unique opportunity to compare practice patterns among nations. According to the study, better care was not explained by doses of erythropoiesis-stimulating agents nor urea kinetics, but by the number of minutes doctors spent with their patients. In Beijing, it was mandatory that a physician is to be present in the dialysis facility when the dialysis machine was running and there were patients on it. The physician was requested to see patients before dialysis started and changed their dialysis prescription if necessary, to make ward rounds to contact each patient on the machine, and to see patients again to evaluate the finished dialysis session and make necessary dialysis prescription changes for the next dialysis session. To our knowledge, whether this practice pattern of intensive patient care favored better patient outcome has not been explored adequately. (2) There is a broad consensus that the dialysis catheter was a dominant driver of morbidity and mortality and accounted for a significant part of mortality differences across countries [8, 9] . For the US 2008 prevalent patients, 55.0% patients were using arterio-venous fistula as their current blood access [7] . This was in total contrast to the Beijing MHD patients. According to the BJHDQCIC ADR 2009 [5] , the first blood access used was by a temporary catheter for 62.6% 2007 incident MHD patients. Arterio venous access accounted for 79.1% 2007 prevalent MHD patients. This huge difference in type of vascular access in prevalent MHD patients could be an explanation for mortality difference between the USRDS and the Beijing cohorts.
There were some limitations of this mortality comparison: (1) the Beijing dataset was not a national dataset (2) primary causes of ESRD other than diabetes, hypertension and glomerular nephritis were merged as one and named 'other', which included unknown, other and missing. 'Other' accounted for around 50% and 15-20% primary causes of ESRD in the Beijing cohorts and in the USRDS cohorts, respectively. The actual causes of ESRD hidden inside 'other' might be different between the Beijing cohorts and the USRDS cohorts. This inside difference could not be adjusted. Fortunately, patients with 'other' causes of ESRD were not included in survival comparison between cohorts. (3) Baseline comorbidities, such as the baseline condition of 'with/without coronary heart disease', or 'the type of blood access' in the Beijing cohorts, were not adjusted to their USRDS counterparts. If Beijing patients seemed 'healthier' than their USRDS counterparts, this could be one of the main reasons for their survival advantages. This could be true, because the Beijing patients were younger than the US patients, and younger might be healthier. Certain age adjustment was performed to solve this problem. However, because of the sample size limitation in Beijing, age was divided into only three groups for adjustment. Although age adjustment was insufficient, the results were still reasonable. The adjusted mortality of Beijing MHD patients was half that of its counterpart in the young age group (20-44 years old age). The same phenomenon was seen in the age group 45-65 years. That is to say, no matter in which age group, US patients always suffered from high mortality compared with their Beijing counterparts. This could be caused by the fact that Beijing patients were generally healthier, no matter younger or older, compared with their US counterparts. But what were the real reasons for this phenomenon? This question would encourage future study, and the answer would increase the quality of patient care.
Although the possibility of baseline comorbidity difference as an explanation for survival difference could not be ruled out, differences in practice pattern (such as time spent on patients by physicians) or race should be the main explanation. According to the data registration report from Shanghai, China, the annual mortality was 7.5% in 2005 for Shanghai MHD patients [10] . This mortality was comparable to that found in our current report and to that reported in BJHDQCIC ADR2011 [6] . Low mortality was seen not only in China. In 2003, the Dialysis Outcome Practice Pattern Study (DOPPS) reported the raw annual mortality in Japan (6.6%), Europe (15.6%) and the US (21.7%) [11] . According to the Japanese Society for Dialysis Therapy (http://www.jsdt.or.jp/), the annual mortality from 2007 to 2009 was around 9.5% for Japanese MHD patients. The observed survival advantage in Asian could be caused by race or practice pattern. Unfortunately, practice pattern was always bound with race; one could not tell whether the survival difference was caused by practice pattern or by race. There was one way to differentiate the effect of these two factors, which was to compare races inside the USRDS. It was reported that USRDS African-Americans had a survival advantage compared with whites after age 40 [12] . This phenomenon suggested that there were survival differences among USRDS patients among races, at least between whites and African-Americans. This survival difference should not be caused by practice pattern, but by race. But ChineseAmerican was merged into Asian-American in the USRDS and their survival cannot be calculated separately. To solve this issue, we suggested that the USRDS data manipulation method be modified by using Chinese-American as a separate race different from Asian-American.
In the current study, we found that annual mortality increased in the Beijing cohorts from 2007 to 2010. This might be attributed to the increasing proportion of patients older than 65 and the increasing proportion of patients with diabetes as the primary cause of ESRD. It was worth noting that annual mortality in the USRDS has been decreasing in recent years in whites, African-Americans and Asian-Americans, despite the trend of age and change of the primary cause of ESRD. This might be caused by improvement in patient care or changes in practice pattern over years, like increased use of arterio-venous fistula.
In conclusion, we reported that the annual mortality for the Beijing MHD patients was lower than their USRDS counterparts, and this difference existed after the baseline demographics were adjusted. The reason why the Beijing patients had this survival advantage was not clear. We made a hypothesis that this survival difference could be attributed to differences in race or practice pattern. More studies are needed to validate our hypothesis. 
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